Biotechnology News and Research

RSS

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Covance Inc., a leading provider of drug development services, announced today that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry.

19 Nov 2009

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Several studies have shown that lipid peroxidation stimulates collagen production in fibroblasts and hepatic stellate cells (HSC), and plays an important role in the development of liver fibrosis. Hepatoprotective effects of green tea against carbon tetrachloride, cholestasis and alcohol induced liver fibrosis were reported in many studies. However, the hepatoprotective effect of green tea in dimethylnitrosamine (DMN)-induced models has not been studied.

18 Nov 2009

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has entered into an agreement with GeneNews (TSX: GEN), of Toronto, Canada, for exclusive rights to market GeneNews’ ColonSentry™, a proprietary blood test for colorectal cancer, in the states of New York and New Jersey.

18 Nov 2009

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will provide insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products at the World Generic Medicines Congress Americas, being held November 17 - 20, 2009 in Washington, DC.

From Parexel 18 Nov 2009

Phase 2/3 study results of Genzyme's APB announced

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme’s Renvela® (sevelamer carbonate).

18 Nov 2009

VINNOVA to provide SEK 3.6 million for Vitrolife’s stem-cell research

Vitrolife: VINNOVA announced in a press release yesterday that they are going to provide support of SEK 3.6 million for Vitrolife’s research project for optimized culture media to enable the clinical use of stem cells. “It is very pleasing news and will enable more intensive work in an area that we very much believe in for the future”, says Magnus Nilsson, Vitrolife’s CEO.

18 Nov 2009

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

18 Nov 2009

Request for pre-IND meeting to discuss IND application for therapeutic vaccine granted by FDA

GeoVax Labs, Inc. (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV.

18 Nov 2009

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.

18 Nov 2009

Asterand to acquire BioSeek

Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, today announces it has signed an agreement to acquire BioSeek Inc.

18 Nov 2009

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C).

18 Nov 2009

On-going Phase 2b study conducted by Roche of ITMN-191 modified

InterMune, Inc. today announced that the on-going Phase 2b study conducted by Roche of ITMN-191 (RG7227) combined with standard of care (SOC) PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin) in HCV treatment-naive patients has been modified.

18 Nov 2009

PolyMedix completes public offering of units for aggregate gross proceeds of $20.7 million

PolyMedix Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a public offering of units for aggregate gross proceeds of $20.7 million.

18 Nov 2009

New encapsulated system may enable doctors to deliver anti-cancer drugs directly to tumors

An encapsulation breakthrough by researchers at the Technion-Israel Institute of Technology may enable doctors to deliver anti-cancer drugs directly to tumors over extended periods of time, while preventing the systemic side effects of chemotherapy and other current cancer treatments.

18 Nov 2009

SIRO Clinpharm and Mediscis team up to expand clinical development plans

SIRO Clinpharm, a global Contract Research Organization (CRO) with bases in India, US, Europe and Israel today announced their alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France.

18 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.

17 Nov 2009

First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009.

17 Nov 2009

Biotechnology News and Research

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Covance and Rules-Based Medicine enter into biomarker alliance and services agreement

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Enzo Biochem to market GeneNews’ ColonSentry in New York and New Jersey

Insights into evolving pharmacovigilance trends and their impact on biosimilars and generic products

Phase 2/3 study results of Genzyme's APB announced

VINNOVA to provide SEK 3.6 million for Vitrolife’s stem-cell research

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Request for pre-IND meeting to discuss IND application for therapeutic vaccine granted by FDA

IBM scientists create one-step point-of-care-diagnostic test based on innovative silicon chip

Asterand to acquire BioSeek

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

On-going Phase 2b study conducted by Roche of ITMN-191 modified

PolyMedix completes public offering of units for aggregate gross proceeds of $20.7 million

New encapsulated system may enable doctors to deliver anti-cancer drugs directly to tumors

SIRO Clinpharm and Mediscis team up to expand clinical development plans

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

First-quarter fiscal 2010 results announced by Senesco Technologies

Biotechnology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News